The first triptan, sumatriptan, was introduced in the U.S. in 1995. Since then, more than BMS-599626 AC480 six drugs in this class available triptans marketed.16 comparable safety profile, but some differences to influence k Can clinical decisions. For example, eletriptan Haupts Chlich by CYP3A4, interactions with other medications medications for a gr Ere the other concern with this agent triptans.17 to be known, makes vasoconstrictors metabolized triptans were obtained with a Hten incidence of associated heart attack and stroke. However, the group said the triptans kardiovaskul Re safety experts with the effects of IS3 Geburtssch To. All 11 pregnancies with exposure of tt in the third quarter resulted in live births without birth defects. The increase of 4.
7% of people report some kind of birth defect, without blemish, is comparable to the expected H FREQUENCY in the general Bev Lkerung, and the overall rate of miscarriage is lower than 14 22% incidence expected. In addition, there were 53 pregnancies with exposure to naratriptan experienced outcomes.25 Of the 48 exposures in the first quarter there were 42 births, miscarriages, 5 and 1 abortion. It was reported a child living with a birth defect, but the child was also sumatriptan w Exposed during the first quarter. The other 5 shots w Occurred during the second quarter, and all resulted in live births without M Reported shortcomings. The types of malformations are not reported in the sumatriptan and naratriptan pregnancy registry. Merck and Company unterh One Database similar to rizatriptan, with regular reports lt Ig updates made available on 31 request.
26 July 2006, 74 women were enrolled in the Pregnancy Registry for Maxalt: 67 prospectively and 7 retrospectively. Of the 67 patients included in the fa Interested parties is 11 lost to follow-up and 21 pregnancies were still anh Dependent. Thus, there are data on 35 pregnancies. Among them there were 30 births, fetal death due to an accident in the line sp Th pregnancy, 3 miscarriages and abortions due to chromosomal abnormalities. There are no data in the report made on the timing of drug exposure in these patients. Of the 7 retrospective reported exposures were three babies with birth defects, as shown in Table 5. All were exposed in the first quarter, but not a model with negative consequences of pregnancy was identified because of the small number of reports.
The data collected in the registers of pregnancy for sumatriptan, naratriptan, rizatriptan, and are of greater Ter importance in determining the safety of medicines through a Bev Lkerung which give a high proportion of women Rf Bearing age are used . The gr Te RESTRICTIONS LIMITATION such a registry is that it relies on voluntary reporting from Budding Uncircumcised in the health professions, and often these reports are made retrospectively, after a negative pregnancy test has occurred. Therefore, the information is always incomplete Complete, and m for may have negatively biased. The first clinical study on the use of triptan may need during the pregnancy was published in 1998 Ver And included a cohort of women who w Used during pregnancy sumatriptan and voluntarily contacted a teratogen information services from 4 participating seeking advice